NASDAQ: LYRA
Lyra Therapeutics Inc Stock Ownership - Who owns Lyra Therapeutics?

Insider buying vs selling

Have Lyra Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Jason CavalierChief Financial Officer2025-07-10684$8.91
$6.09kSell
Maria PalasisPresident CEO2025-07-101,565$8.91
$13.94kSell

1 of 1

LYRA insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when LYRA insiders and whales buy or sell their stock.

LYRA Shareholders

What type of owners hold Lyra Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Edward T. Anderson160.55%2,640,228$16.82MInsider
Perceptive Advisors LLC156.70%2,576,892$16.41MInsider
Nbvm GP LLC153.35%2,521,745$16.06MInsider
Maria Palasis66.80%1,098,435$7.00MInsider
Harlan Waksal32.65%536,966$3.42MInsider
Jason Cavalier31.58%519,316$3.31MInsider
Perceptive Advisors LLC15.52%255,150$1.63MInstitution
Soleus Private Equity GP I LLC9.43%155,000$987.35kInsider
Sabby Management LLC7.65%125,729$800.89kInstitution
Carmichael Roberts3.55%58,414$372.10kInsider

1 of 3

LYRA vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
LYRA4.59%95.41%Net Selling
IMNN19.70%80.30%Net BuyingNet Buying
ACXP50.36%49.64%Net Buying
APM0.62%29.22%
XTLB0.03%12.85%

Lyra Therapeutics Stock Ownership FAQ

Who owns Lyra Therapeutics?

Lyra Therapeutics (NASDAQ: LYRA) is owned by 30.04% institutional shareholders, 624.49% Lyra Therapeutics insiders, and 0.00% retail investors. Edward T. Anderson is the largest individual Lyra Therapeutics shareholder, owning 2.64M shares representing 160.55% of the company. Edward T. Anderson's Lyra Therapeutics shares are currently valued at $16.82M.

If you're new to stock investing, here's how to buy Lyra Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.